Latest & greatest articles for pioglitazone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pioglitazone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pioglitazone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pioglitazone

61. Pioglitazone and cardiovascular risk: a comprehensive meta-analysis of randomized clinical trials

Pioglitazone and cardiovascular risk: a comprehensive meta-analysis of randomized clinical trials Pioglitazone and cardiovascular risk: a comprehensive meta-analysis of randomized clinical trials Pioglitazone and cardiovascular risk: a comprehensive meta-analysis of randomized clinical trials Mannucci E, Monami M, Lamanna C, Gensini G F, Marchionni N CRD summary This review found that pioglitazone was not associated with increased risk of cardiovascular events. Insufficient information (...) presented and the conduct of the review made it difficult to draw any conclusions about the evidence presented and the reliability of the authors' conclusions. Authors' objectives To assess the effect of pioglitazone on the risk of non-fatal coronary events, cardiovascular mortality and all-cause mortality. Searching MEDLINE was searched from inception to 31 August 2007 for randomised controlled trials of human subjects published in English. Searches were also undertaken on the Food and Drug

DARE.2008

62. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials

Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials Nagajothi N, Adigopula S, Balamuthusamy S, Velazquez-Cecena J L, Raghunathan K (...) , Khraisat A, Singh S, Molnar J, Khosla S, Benatar D CRD summary The authors concluded that pioglitazone did not appear to increase myocardial infarction (MI) and may reduce stroke and revascularisation. Conclusions regarding myocardial infarction appeared supported by the evidence, but the results for stroke and revascularisation were not statistically significant and may not be reliable. Authors' objectives To evaluate the effect of pioglitazone on cardiovascular outcomes. Searching MEDLINE, EMBASE

DARE.2008

63. Pioglitazone reduced MI and acute coronary syndrome but not other cardiovascular events in patients with type 2 diabetes and previous MI

Pioglitazone reduced MI and acute coronary syndrome but not other cardiovascular events in patients with type 2 diabetes and previous MI Pioglitazone reduced MI and acute coronary syndrome but not other cardiovascular events in patients with type 2 diabetes and previous MI | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pioglitazone reduced MI and acute coronary syndrome but not other cardiovascular events in patients with type 2 diabetes and previous MI Article Text Therapeutics Pioglitazone reduced MI and acute coronary syndrome but not other

Evidence-Based Medicine (Requires free registration)2008

64. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. 18378631 2008 04 04 2008 04 07 2016 11 24 1538-3598 299 13 2008 Apr 02 JAMA JAMA Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. 1561-73 10.1001/jama.299.13.1561 No antidiabetic regimen has demonstrated the ability (...) to reduce progression of coronary atherosclerosis. Commonly used oral glucose-lowering agents include sulfonylureas, which are insulin secretagogues, and thiazolidinediones, which are insulin sensitizers. To compare the effects of an insulin sensitizer, pioglitazone, with an insulin secretagogue, glimepiride, on the progression of coronary atherosclerosis in patients with type 2 diabetes. Double-blind, randomized, multicenter trial at 97 academic and community hospitals in North and South America

JAMA2008

66. Pioglitazone did not reduce macrovascular complications and increased HF in type 2 diabetes with macrovascular disease

Pioglitazone did not reduce macrovascular complications and increased HF in type 2 diabetes with macrovascular disease Pioglitazone did not reduce macrovascular complications and increased HF in type 2 diabetes with macrovascular disease | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pioglitazone did not reduce macrovascular complications and increased HF in type 2 diabetes with macrovascular disease Article Text Therapeutics Pioglitazone did not reduce macrovascular complications and increased HF in type 2 diabetes with macrovascular disease Statistics

Evidence-Based Medicine (Requires free registration)2007

67. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK

PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK Valentine W J, Bottomley J M, Palmer A J, Brandle M, Foos V, Williams R, Dormandy J A, Yates J, Tan M H, Massi-Benedetti M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the addition of pioglitazone to existing treatments ("add-on" therapy) for patients with Type 2 diabetes and a history of macrovascular disease. Pioglitazone could be given at 15, 30 or 45 mg/day. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis and cost-utility

NHS Economic Evaluation Database.2007

68. Rosiglitazone and pioglitazone: a critical  appraisal of de PROactive and DREAM trials

Rosiglitazone and pioglitazone: a critical  appraisal of de PROactive and DREAM trials Volumen 15. DTB Navarre. Vol 15, No 2. March - April 2007 - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : : : DTB Navarre. Vol 15, No 2. March - April 2007 DTB Navarre. Vol 15, No 2. March - April 2007 Content tools Share it Rosiglitazone and pioglitazone: A Critical Appraisal of the PROactive and DREAM trials Recently, two placebo controlled trials (...) studying thiazolidinediones have been published. In one, the effect of pioglitazone on macrovascular events in secondary prevention patients with type 2 diabetes was evaluated (the PROactive trial). In the second, the effect of rosiglitazone on global mortality and incidence of diabetes was tested in patients with impaired fasting glucose or impaired glucose tolerance or both (the DREAM trial). Authors: Javier Gorricho et al. Drug Information Unit. Navarre Regional Health Service. Spain. Enviar

Drug and Therapeutics Bulletin of Navarre (Spain)2007

71. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial

Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results (...) of a randomized clinical trial Umpierrez G, Issa M, Vlajnic A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The authors studied glimepiride and pioglitazone for the treatment of Type 2 diabetes. Glimepiride was given once daily at a starting dose of 2 mg

NHS Economic Evaluation Database.2006

72. Pioglitazone 15mg/metformin 850mg hydrochloride (Competact)

Pioglitazone 15mg/metformin 850mg hydrochloride (Competact) Scottish Medicines Consortium Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6989 E-mail: Rosie.Murray@nhshealthquality.org Chairman Professor David Webb Pioglitazone 15mg/metformin 850mg hydrochloride (Competact) (No. 252/06) Takeda UK Ltd Product Update 7 April 2006 (Issued August 2006) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises the NHS Boards (...) and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission pioglitazone 15mg/metformin 850m g hydrochloride (Competact) is accepted for restricted use in NHSScotland for the treatment of type 2 diabetes mellitus. It should be used for overweight patients who are unable to achieve sufficient glycaemic control at their maximally tolerated doses of oral metformin alone. It is restricted to patients who

Scottish Medicines Consortium2006

73. Duetact (pioglitazone HCl + glimepiride)

Duetact (pioglitazone HCl + glimepiride) Drug Approval Package: Duetact (pioglitazone HCl + glimepiride) NDA #021925 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Duetact (pioglitazone HCl + glimepiride) Company: Takeda Global Research & Development Center, Inc. Application No.: 021925 Approval Date: 07/28/2006 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: September 4, 2008 Note: Documents in PDF format require the . - - Links

FDA - Drug Approval Package2006

74. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. 17135584 2006 11 30 2006 12 07 2012 11 15 1533-4406 355 22 2006 Nov 30 The New England journal of medicine N. Engl. J. Med. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. 2297-307 No pharmacologic therapy has conclusively proved to be effective for the treatment of nonalcoholic steatohepatitis, which is characterized by insulin resistance, steatosis (...) , and necroinflammation with or without centrilobular fibrosis. Pioglitazone is a thiazolidinedione that ameliorates insulin resistance and improves glucose and lipid metabolism in type 2 diabetes mellitus. We randomly assigned 55 patients with impaired glucose tolerance or type 2 diabetes and liver biopsy-confirmed nonalcoholic steatohepatitis to 6 months of treatment with a hypocaloric diet (a reduction of 500 kcal per day in relation to the calculated daily intake required to maintain body weight) plus

NEJM2006

75. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. 17101640 2006 12 06 2006 12 11 2016 11 24 1538-3598 296 21 2006 Dec 06 JAMA JAMA Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. 2572-81 Carotid artery intima-media thickness (CIMT) is a marker of coronary atherosclerosis and independently predicts cardiovascular events, which are increased (...) in type 2 diabetes mellitus (DM). While studies of relatively short duration have suggested that thiazolidinediones such as pioglitazone might reduce progression of CIMT in persons with diabetes, the results of longer studies have been less clear. To evaluate the effect of pioglitazone vs glimepiride on changes in CIMT of the common carotid artery in patients with type 2 DM. Randomized, double-blind, comparator-controlled, multicenter trial in patients with type 2 DM conducted at 28 clinical sites

JAMA2006

77. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. 16214598 2005 10 10 2005 10 21 2016 01 11 1474-547X 366 9493 2005 Oct 08 Lancet (London, England) Lancet Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled (...) trial. 1279-89 Patients with type 2 diabetes are at high risk of fatal and non-fatal myocardial infarction and stroke. There is indirect evidence that agonists of peroxisome proliferator-activated receptor gamma (PPAR gamma) could reduce macrovascular complications. Our aim, therefore, was to ascertain whether pioglitazone reduces macrovascular morbidity and mortality in high-risk patients with type 2 diabetes. We did a prospective, randomised controlled trial in 5238 patients with type 2 diabetes

Lancet2005

78. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation

Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found

NIHR HTA programme2004

79. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation

Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation Czoski-Murray C (...) , Warren E, Chilcott J, Beverley C, Psyllaki M A, Cowan J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki M A, Cowan J. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. Health

Health Technology Assessment (HTA) Database.2004

80. Comparative clinical and budget evaluations of rosiglitazone and pioglitazone with other anti-diabetic agents

Comparative clinical and budget evaluations of rosiglitazone and pioglitazone with other anti-diabetic agents Comparative clinical and budget evaluations of rosiglitazone and pioglitazone with other anti-diabetic agents Comparative clinical and budget evaluations of rosiglitazone and pioglitazone with other anti-diabetic agents Boucher M, McAuley L, Brown A, Keely E, Skidmore B Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Boucher M, McAuley L, Brown A, Keely E, Skidmore B. Comparative clinical and budget evaluations of rosiglitazone and pioglitazone with other anti-diabetic agents. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2003: 17 Authors' objectives 1. To evaluate the evidence that compares rosiglitazone or pioglitazone with other oral anti-diabetic agents (including insulin), either when used

Health Technology Assessment (HTA) Database.2003